



參考資料

1. Hong Kong Cancer Registry, Hospital Authority. Hong Kong Cancer Statistics 2017. Published October 2019.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Painting, firefighting, and shiftwork. *IARC Monogr Eval Carcinog Risks to Humans*. 2010;98:9-764.
3. International Agency for Research on Cancer. List of Classifications by cancer sites with sufficient or limited evidence in humans, Volumes 1 to 127. https://monographs.iarc.fr/wp-content/uploads/2019/07/Classifications_by_cancer_site_127.pdf. Updated June 26, 2020. Accessed September 1, 2020.
4. Papantoniou K, Castaño-Vinyals G, Espinosa A, et al. Breast cancer risk and night shift work in a case-control study in a Spanish population. *Eur J Epidemiol*. 2016;31(9):867-878. doi:10.1007/s10654-015-0073-y.
5. Census and Statistics Department (HK). 2019 Report on Annual Earnings and Hours Survey. <https://www.statistics.gov.hk/pub/B10500142019AN19B0100.pdf>. Published April 2020. Accessed September 1, 2020.
6. Hvidberg L, Pedersen AF, Wulff CN, Vedsted P. Cancer awareness and socio-economic position: Results from a population-based study in Denmark. *BMC Cancer*. 2014;14(1):581. doi:10.1186/1471-2407-14-581.
7. Gürdal SÖ, Saraçoğlu GV, Oran EŞ, Yankol Y, Soybir GR. The effects of educational level on breast cancer awareness: A cross-sectional study in Turkey. *Asian Pacific J Cancer Prev*. 2012;13(1):295-300. doi:10.7314/APJCP.2012.13.1.295.
8. Yeung MPS, Chan EYY, Wong SYS, Yip BHK, Cheung PSY. Hong Kong female's breast cancer awareness measure: Cross-sectional survey. *World J Clin Oncol*. 2019;10(2):98-109. doi:10.5306/wjco.v10.i2.98.
9. Hong Kong Breast Cancer Foundation. *Hong Kong Breast Cancer Registry Bulletin Issue 2: Socio-Economic Disparities in Breast Cancer Screening Practice and Cancer Staging in Hong Kong*. Hong Kong Breast Cancer Foundation; 2012.
10. Senie RT, Saftlas AF, Brinton LA, Hoover RN. Is breast size a predictor of breast cancer risk or the laterality of the tumor? *Cancer Causes Control*. 1993;4(3):203-208. doi:10.1007/BF00051314.
11. Kato I, Beinart C, Bleich A, Su S, Kim M, Toniolo PG. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States). *Cancer Causes Control*. 1995;6(5):431-438. doi:10.1007/BF00052183.
12. Egan KM, Newcomb PA, Titus-Ernstoff L, et al. The relation of breast size to breast cancer risk in postmenopausal women (United States). *Cancer Causes Control*. 1999;10(2):115-118. doi:10.1023/A:1008801131831.
13. Ooi BNS, Loh H, Ho PJ, et al. The genetic interplay between body mass index, breast size and breast cancer risk: A Mendelian randomization analysis. *Int J Epidemiol*. 2019;48(3):781-794. doi:10.1093/ije/dyz124.
14. del Carmen MG, Halpern EF, Kopans DB, et al. Mammographic breast density and race. *AJR Am J Roentgenol*. 2007;188(4):1147-1150. doi:10.2214/AJR.06.0619.
15. National Cancer Institute. Dense Breasts: Answers to Commonly Asked Questions. <https://www.cancer.gov/types/breast/breast-changes/dense-breasts>. Updated July 14, 2020. Accessed September 1, 2020.
16. Census and Statistics Department (HK). Thematic Household Survey Report No. 70: Pattern of Smoking. <https://www.statistics.gov.hk/pub/B11302702020XXXXB0100.pdf>. Published June 2020. Accessed September 1, 2020.

17. Chapter 6 Cancer: Breast Cancer. In: U.S. Department of Health and Human Services. *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014:230.
18. Hong Kong Breast Cancer Foundation. *Hong Kong Breast Cancer Registry Bulletin Issue 9: Risk factors for breast cancer in Hong Kong women: A case-control study*. Hong Kong Breast Cancer Foundation; 2018.
19. World Cancer Research Fund / American Institute for Cancer Research. Diet, nutrition, physical activity and breast cancer. *Continuous Update Project Expert Report 2018*. <https://www.wcrf.org/sites/default/files/Breast-cancer-report.pdf>. Published May 2018. Accessed September 1, 2020.
20. Centre for Health Protection Department of Health (HK). Behavioural Risk Factor Survey (April 2016). https://www.chp.gov.hk/files/pdf/brfa_report_april_2016_eng.pdf. Published May 2017. Accessed September 1, 2020.
21. Cheraghi Z, Poorolaja IJ, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: A meta-analysis. *PLoS One*. 2012;7(12):e51446. doi:10.1371/journal.pone.0051446.
22. Body Mass Index (BMI) Distribution. Centre for Health Protection, Department of Health (HK). <https://www.chp.gov.hk/en/statistics/data/10/280/6621.html>. Updated December 2017. Accessed September 1, 2020.
23. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. *Lancet*. 2001;358(9291):1389-1399. doi:10.1016/S0140-6736(01)06524-2.
24. Pharoah PDP, Day NE, Duffy S, Easton DF, Ponder BAJ. Family history and the risk of breast cancer: A systematic review and meta-analysis. *Int J Cancer*. 1997;71(5):800-809. doi:10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B.
25. Kwong A, Shin VY, Ho JCW, et al. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. *J Med Genet*. 2016;53:15-23. doi:10.1136/jmedgenet-2015-103132.
26. Kwong A, Shin VY, Au CH, et al. Detection of germline mutation in hereditary breast and/or ovarian cancers by next-generation sequencing on a four-gene panel. *J Mol Diagnostics*. 2016;18(4):580-594. doi:10.1016/j.jmoldx.2016.03.005.
27. Ibrahim EM, Abouelkhair KM, Kazkaz GA, Elmasri OA, Al-Foheidi M. Risk of second breast cancer in female Hodgkin's lymphoma survivors: A meta-analysis. *BMC Cancer*. 2012;12:197. doi:10.1186/1471-2407-12-197.
28. Caini S, Boniol M, Botteri E, et al. The risk of developing a second primary cancer in melanoma patients: A comprehensive review of the literature and meta-analysis. *J Dermatol Sci*. 2014;75(1):3-9. doi:10.1016/j.jdermsci.2014.02.007.
29. Jégu J, Colonna M, Daubisse-Marliac L, et al. The effect of patient characteristics on second primary cancer risk in France. *BMC Cancer*. 2014;14:94. doi:10.1186/1471-2407-14-94.
30. Youlten DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: A retrospective cohort study. *BMC Cancer*. 2011;11:83. doi:10.1186/1471-2407-11-83.
31. Chuang SC, Scélo G, Lee YCA, et al. Risks of second primary cancer among patients with major histological types of lung cancers in both men and women. *Br J Cancer*. 2010;102(7):1190-1195. doi:10.1038/sj.bjc.6605616.
32. Chaturvedi AK, Kleinerman RA, Hildesheim A, et al. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. *J Clin Oncol*. 2009;27(6):967-973. doi:10.1200/JCO.2008.18.4549.



33. Zhou WB, Xue DQ, Liu XA, Ding Q, Wang S. The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: A meta-analysis. *J Cancer Res Clin Oncol*. 2011;137:1053-1060. doi:10.1007/s00432-011-0979-z.
34. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *Lancet*. 1996;347(9017):1713-1727. doi:10.1016/S0140-6736(96)90806-5.
35. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. *N Engl J Med*. 2017;377(23):2228-2239. doi:10.1056/NEJMoa1700732.
36. Urban M, Banks E, Egger S, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: Case-control study. *PLoS Med*. 2012;9(3):e1001182. doi:10.1371/journal.pmed.1001182.
37. Li CI, Beaber EF, Tang MTC, Porter PL, Daling JR, Malone KE. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. *Cancer Res*. 2012;72(8):2028-2035. doi:10.1158/0008-5472.CAN-11-4064.
38. Sweeney C, Giuliano AR, Baumgartner KB, et al. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. *Int J Cancer*. 2007;121(11):2517-2523. doi:10.1002/ijc.22970.
39. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. *Am J Epidemiol*. 2000;151(4):396-403. doi:10.1093/oxfordjournals.aje.a010219.
40. Strom BL, Berlin JA, Weber AL, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. *Contraception*. 2004;69(5):353-360. doi:10.1016/j.contraception.2003.12.015.
41. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. *Arch Pathol Lab Med*. 2018;142(11):1364-1382. doi:10.5858/arpa.2018-0902-SA.
42. Roth MY, Elmore JG, Yi-Frazier JP, Reisch LM, Oster NV, Miglioretti DL. Self-detection remains a key method of breast cancer detection for U.S. women. *J Women's Heal*. 2011;20(8):1135-1139. doi:10.1089/jwh.2010.2493.
43. Ernst MF, Roukema JA, Coebergh JW, et al. Breast cancers found by screening: Earlier detection, lower malignant potential or both? *Breast Cancer Res Treat*. 2002;76(1):19-25. doi:10.1023/A:1020213817562.
44. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: A systematic review. *Lancet*. 1999;353(9159):1119-1126. doi:10.1016/S0140-6736(99)02143-1.
45. Amin MB, Edge S, Greene F, et al. (eds). *AJCC Cancer Staging System (8th Edition)*. New York, NY: Springer International Publishing; 2017. doi:10.1007/978-3-319-40618-3_48.
46. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. *Ann Oncol*. 2011;22(8):1736-1747. doi:10.1093/annonc/mdr304.
47. Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: An overview. *BMC Med*. 2015;13:195. doi:10.1186/s12916-015-0439-8.